Immunovant, Inc. (NASDAQ:IMVT) Q4 2022 Earnings Conference Call June 8, 2022 8:00 AM ET

Company Participants

Pete Salzmann - CEO

Conference Call Participants

Robyn Karnauskas - Truist Securities

Derek Archila - Wells Fargo

Thomas Smith - SVB Leerink

Douglas Tsao - H.C. Wainwright

Operator

Good morning. My name is Melissa and I will serve as your conference call operator. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation [Operator Instructions]. As a reminder, this call is being recorded. Joining me on the call today will be Dr. Pete Salzmann, Chief Executive Officer of Immunovant.

Before we begin, I would like to remind everyone that today’s conference call will include certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

These forward-looking statements include, among other things, statements regarding Immunovant’s plan to initiate two Phase 3 clinical trials for batoclimab in TED in the second half of calendar year 2022, with an expected topline data readout in the first half of calendar year 2025, and its plan to initiate a Phase 3 clinical trial in MG by the end of June 2022 with an expected readout in the second half of calendar year 2024; Immunovant’s plans to develop batoclimab across a broad range of autoimmune indications; the potential efficacy and safety of Immunovant’s product candidate; Immunovant’s expectations regarding the timing, design and results of its clinical trials, including the timing of future data readouts; and the announcement of additional indications, and whether if approved batoclimab will be successfully distributed, marketed, and commercialized.

All forward-looking statements are based on estimates and assumptions by Immunovant’s management that although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Immunovant expects. For more information, investors are encouraged to review Immunovant’s annual report on Form 10K for the year ended March 31, 2022, filed with the SEC on June 8, 2022, and Immunovant’s subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made, and Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Now I would like to turn the call over to Dr. Pete Salzmann. Thank you. Dr. Salzmann, please go ahead.